Findings

What do systematic reviews say?

2 questions · 2 findings · 1 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 2 · 100%GRADE not reported 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 0 · 0%High 0 · 0%

Alemtuzumab 24 mg vs interferon beta‐1a

New or enlarging T2‐hyperintense lesions · adults with multiple sclerosis Interventions: immunosuppressive and immunomodulatory drugs Comparator: placebo Outcome: withdrawals due to…

The review found no eligible studies for this question.

1 finding from 1 review

Alemtuzumab for multiple sclerosis 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Alemtuzumab 12 mg vs interferon beta‐1a

Number of participants with new or enlarging T2‐hyperintense lesions on MRI · adults with relapsing–remitting multiple sclerosis

The review found no eligible studies for this question.

1 finding from 1 review

Alemtuzumab for multiple sclerosis 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found